ATLANTA, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced that it has signed a new contract for the use of RevID with a 400-bed, Oracle Health-EHR based health system with facilities in Western Texas. The deal was closed in partnership with Oracle Health.
Streamline Health is leading an industry movement to improve hospital financial performance through pre-bill technology solutions. RevID’s automated charge reconciliation enables hospitals to capture 100% of earned revenue by eliminating charge capture gaps and accelerates cash flow by ensuring that providers can accurately capture, bill and ultimately be paid for all the care they provide. Enabled by seamless integration with Oracle Health’s Soarian billing platform, RevID positions health systems to enhance financial operations by automating and optimizing charge reconciliation processes for greater accuracy and efficiency.
“Texas is home to some of the nation’s most forward-thinking healthcare providers, and is an ideal market for continued expansion,” stated Ben Stilwill, Chief Executive Officer. “Our growing partnership with Oracle Health strengthens our ability to deliver pre-bill solutions that seamlessly integrate with leading EHR platforms. We look forward to extending our footprint across Texas and beyond.”
About Streamline Health
Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net
Last Trade: | US$5.33 |
Daily Volume: | 0 |
Market Cap: | US$23.240M |
May 01, 2025 January 22, 2025 December 16, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load